Accordingly, genetic depletion of AhR in BRAFi‐resistant SKMel28 melanoma cells (SK28R) by CRISPR Cas9 technology (AhR KO; Fig EV1A) significantly reduced their resistance to various BRAFi (vemurafenib, dabrafenib, and encorafenib; Fig 1A). The gene discussed is AHR; the disease is melanoma.